Trial Profile
Efficacy of Treatment Sequences in Patients With ALK and ROS-1 Positive Non-small Cell Lung Cancer Who Received Lorlatinib as Part of the French Expanded Access Program
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 16 Mar 2022
Price :
$35
*
At a glance
- Drugs Lorlatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Acronyms LORLATU
- 09 Mar 2022 Results published in the European Journal of Cancer
- 19 Oct 2020 Status changed from recruiting to completed.
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress